0001093557-24-000062.txt : 20240410
0001093557-24-000062.hdr.sgml : 20240410
20240410160459
ACCESSION NUMBER: 0001093557-24-000062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240408
FILED AS OF DATE: 20240410
DATE AS OF CHANGE: 20240410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAYER KEVIN R
CENTRAL INDEX KEY: 0001286858
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51222
FILM NUMBER: 24835773
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DEXCOM INC
CENTRAL INDEX KEY: 0001093557
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 330857544
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582000200
MAIL ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-04-08
0
0001093557
DEXCOM INC
DXCM
0001286858
SAYER KEVIN R
6340 SEQUENCE DRIVE
SAN DIEGO
CA
92121
1
1
0
0
President CEO and Chairman
1
Common Stock
2024-04-08
4
S
0
27272
137.9616
D
306254
D
Common Stock
2024-04-08
4
S
0
22361
138.7079
D
283893
D
On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.
This transaction was executed in multiple trades at prices ranging from $137.61 to $138.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.
This transaction was executed in multiple trades at prices ranging from $138.385 to $139.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
By: /s/ Jereme M Sylvain For: Kevin R Sayer
2024-04-10